Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 108
---
, the information omitted from                                   
 the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed 
 by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration    
 statement as of the time it was declared effective.                                                                                        |

| (2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment                          
 that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and 
 the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.                            |

| 56 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements
of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-1 and has duly caused this Post-Effective Amendment No. 2 to the Registration Statements
on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Cardiff, Wales, on this 17th day of
November, 2025.

| BIODEXA PHARMACEUTICALS PLC |                                                   |
| By:                         | /s/ Stephen Stamp                                 |
|                             | Stephen Stamp                                     |
|                             | Chief Executive Officer & Chief Financial Officer |

Pursuant to the requirements of the Securities Act of 1933,
as amended, this Post-Effective Amendment No. 2 to the Registration Statement on Form F-1 has been signed by the following persons in
the capacities and on the date indicated.

| Name and Signature    
 /s/ Stephen Stamp     | Title(s)                                                     
 Chief Executive Officer & Chief Financial Officer, Director  | Date              
 November 17, 2025 |
|:----------------------|:-------------------------------------------------------------|:------------------|
| Stephen Stamp         | -Principal Executive Officer and Principal Financial Officer |                   |
| *                     | Non-Executive Chairman of the Board                          | November 17, 2025 |
| Stephen Parker        |                                                              |                   |
| *                     | Senior Independent Non-Executive Director                    | November 17, 2025 |
| Simon Turton, Ph.D.   |                                                              |                   |
| *                     | Non-